Who Paid My Doc
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evalua
Research payments
$1,430,082
Through program year 2025, $1,430,082 in research payments was reported against A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evalua, across 536 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $863,038 | 386 |
| 2024 | Research | $567,045 | 150 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Barbara Burtness New Haven, CT Named on 60 payments
- Zeeshan Ali Greenville, SC Named on 44 payments
- Yungpo Su Council Bluffs, IA Named on 37 payments
- Gang Tian Germantown, TN Named on 31 payments
- Jerome Goldschmidt Salem, VA Named on 28 payments
- Najeff Waseem Eldersburg, MD Named on 26 payments
- Ryan Kendle Los Angeles, CA Named on 22 payments
- Joseph Merriman Nashville, TN Named on 19 payments
- Douglas Laux Iowa City, IA Named on 16 payments
- Susanne Arnold Lexington, KY Named on 14 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.